Table 5.

JAK2V617F⁺ SCID repopulating cells can be preferentially eliminated by sequential treatment with CMAs

Patient#	Treatment	% JAK2V617F in granulocytes	Number of CD34+ cells transplanted ×105	Duration of engraftment, mo	% CD45+ cells in BM	% JAK2V617F in BM hCD45+ cells
4		86		2
	Primary CD34+ cells		6.4		4.4	71.5
	Cytokines alone		10		0.2	34.7
	Cytokines + 5azaD/TSA		4.2		0.2	6.8
6		77		4
	Cytokines alone		2.1		0.04	74.5
	Cytokines + 5azaD/TSA		1.5		0.1	22.5
9		75		4
	Cytokines alone		5.1		0.1	82.4
	Cytokines + 5azaD/TSA		3.5		0.1	8.8
10		70		4
	Cytokines alone		0.8		0.1	79.9
	Cytokines + 5azaD/TSA		0.9		0.1	28.8
1		80		6
	Primary CD34+ cells		13		0.2	82.5
	Cytokines alone		14		0.1	27.1
	Cytokines + 5azaD/SAHA		7		0.1	3.6
3		35		6
	Primary CD34+ cells		1.3		0.1	97.6
	Cytokines alone		0.8		0.05	41.5
	Cytokines + 5azaD/SAHA		0.7		0.1	7.4
12		37		6
	Primary CD34+ cells		20.6		2.7	92.8
	Cytokines alone		1.7		0.2	94.9
	Cytokines + 5azaD/SAHA		0.7		0.4	17.8
6		77		6
	Cytokines alone		0.5		0.05	84.4
	Cytokines + 5azaD/SAHA		0.4		0.05	40.4

The percentage of JAK2V617F allele from granulocytes of PMF patients or from human CD45⁺ cells isolated from the BM of NOD/SCID/IL2Rγ^null mice was determined by real-time quantitative kinetic PCR assay using allelic discrimination method.